Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

BACKGROUND: Prostate-specific antigen (PSA) based screening for prostate cancer (PCa) has been shown to reduce prostate specific mortality by 20% in an intention to screen (ITS) analysis in a randomised trial (European Randomised Study of Screening for Prostate Cancer [ERSPC]). This effect may be di...

Full description

Bibliographic Details
Main Authors:	Roobol, M, Kerkhof, M, Schröder, F, Cuzick, J, Sasieni, P, Hakama, M, Stenman, U, Ciatto, S, Nelen, V, Kwiatkowski, M, Lujan, M, Lilja, H, Zappa, M, Denis, L, Recker, F, Berenguer, A, Ruutu, M, Kujala, P, Bangma, C, Aus, G, Tammela, T, Villers, A, Rebillard, X, Moss, S, de Koning, H
Format:	Journal article
Language:	English
Published:	2009

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Similar Items